Lipocine vs TherapeuticsMD
LPCN and TXMD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LPCN and TXMD compare
TherapeuticsMD is the larger company, worth 1.6 times as much as Lipocine ($21.4M against $13.1M).
TherapeuticsMD grew revenue faster over the last twelve months (27.8% versus −13.4% for Lipocine).
TherapeuticsMD keeps more of each dollar of sales as profit, with a net margin of −6.6% compared with −249% at Lipocine.
TherapeuticsMD scores higher on the StockData Score (12 against 11 for Lipocine), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LPCN | TXMD |
|---|---|---|
| Size and price | ||
| Market cap | $13.1M | $21.4M |
| Share price | $1.59 | $1.85 |
| Change, 1 year | −45.0% | 37.0% |
| Change, 5 years | −92.0% | −93.5% |
| Beta (5Y) | 0.65 | 0.66 |
| Employees | 14 | 1 |
| StockData Score | ||
| Total score | 11 | 12 (better) |
| Valuation score | 3 | 3 |
| Growth score | 1 | 1 |
| Performance score | 2 | 3 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.5× (better) | 6.5× |
| P/B | 0.6× (better) | 0.8× |
| Fair value | $3.42 | $2.64 |
| Margin of safety | 53.6% (better) | 29.9% |
| Growth | ||
| Revenue growth (TTM) | −13.4% | 27.8% (better) |
| Revenue growth, 5Y average | – | −45.8% |
| Profitability | ||
| Operating margin | −269% | −121% (better) |
| Net margin | −249% | −6.6% (better) |
| Return on equity | −52.9% | −0.80% (better) |
| Return on invested capital | – | −15.9% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 11.36 (better) | 3.22 |
| Altman Z-score | −9.37 (better) | −34.19 |
| Piotroski F-score | 1 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | −123% | – |
| Shareholder yield | −123% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 36.2% | 31.7% |
| Held by insiders | 8.4% | 1.6% |
| Insider net buying, 12 months | $517K (better) | $14.0K |
| Short interest, % of float | 4.3% | 0.27% |
Go deeper
- LPCN stock overview
- LPCN income statement
- LPCN valuation and score
- TXMD stock overview
- TXMD income statement
- TXMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.